Combining checkpoint blockade with inhibitors of the immunosuppressive cytokine TGFβ potentiates curative, CD8 T cell-dependent anti-tumor immunity both in immune-excluded8,12,13 and other preclinical models12,14–20. Here, CD8A is linked to neoplasm.